Inhibition and treatment of prostate cancer metastasis
AssigneeNorthwestern University
InventorsRaymond C. Bergan, Karl A. Scheidt
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.
Claims51
A method for inhibiting prostate cancer metastasis, comprising:
- administering a compound having formula:
- to a subject having prostate cancer;
- wherein A is O, C═O, CHOH, C═NR, or CH2;
- X is C═O, O or NH;
- Y is O, NH, CR9═CR10, or CH═N;
- Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10;
- the dashed line represents an optional double bond;
- R is H or a substituted or unsubstituted alkyl group;
- R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups;
- R2 is selected from the group consisting of H, OH, F and Cl;
- or is absent when the optional double bond is present;
- R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups;
- wherein said compound is not genistein.
A pharmaceutical preparation comprising a compound having formula:
- wherein A is O, C═O, CHOH, C═NR, or CH2;
- X is C═O, O or NH;
- Y is O, NH, CR9═CR10, or CH═N;
- Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10;
- the dashed line represents an optional double bond;
- R is H or a substituted or unsubstituted alkyl group;
- R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups;
- R2 is selected from the group consisting of H, OH, F and Cl;
- or is absent when the optional double bond is present;
- R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups;
- wherein said compound is not genistein.
A compound having the formula:
A compound having the formula:
A method for inhibiting prostate cancer metastasis in a subject, comprising activating the endoglin pathway in said subject.
A method for preventing prostate cancer cell invasion in a subject, comprising:
- administering a compound having formula:
- to said subject;
- wherein A is O, C═O, CHOH, C═NR, or CH2;
- X is C═O, O or NH;
- Y is O, NH, CR9═CR10, or CH═N;
- Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10;
- the dashed line represents an optional double bond;
- R is H or a substituted or unsubstituted alkyl group;
- R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups;
- R2 is selected from the group consisting of H, OH, F and Cl;
- or is absent when the optional double bond is present;
- R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups;
- wherein said compound is not genistein.
A method for preventing prostate cancer cell invasion in a subject, comprising:
- administering a compound selected from the group consisting of
A method of preventing invasion of a prostate cell through the basement membrane into the prostate gland in a subject, comprising:
- administering a compound having formula:
- to said subject;
- wherein A is O, C═O, CHOH, C═NR, or CH2;
- X is C═O, O or NH;
- Y is O, NH, CR9═CR10, or CH═N;
- Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10;
- the dashed line represents an optional double bond;
- R is H or a substituted or unsubstituted alkyl group;
- R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups;
- R2 is selected from the group consisting of H, OH, F and Cl;
- or is absent when the optional double bond is present;
- R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups;
- wherein said compound is not genistein.
A method of preventing invasion of a prostate cell through the basement membrane into the prostate gland in a subject, comprising:
- administering a compound selected from the group consisting of
A method for preventing prostate cancer in a subject, comprising:
- administering a compound having formula:
- to said subject;
- wherein A is O, C═O, CHOH, C═NR, or CH2;
- X is C═O, O or NH;
- Y is O, NH, CR9═CR10, or CH═N;
- Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10;
- the dashed line represents an optional double bond;
- R is H or a substituted or unsubstituted alkyl group;
- R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups;
- R2 is selected from the group consisting of H, OH, F and Cl;
- or is absent when the optional double bond is present;
- R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups;
- wherein said compound is not genistein.
A method of preventing prostate cancer in a subject, comprising:
- administering a compound selected from the group consisting of
Dependencies are inferred from the claim text.